anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
CETRAXAL (ciprofloxacin otic solution) 0.2% contains the synthetic antimicrobial agent ciprofloxacin hydrochloride. CETRAXAL is a sterile, preservative-free solution for otic use. Each single use container of CETRAXAL delivers 0.25 mL of solution equivalent to 0.5 mg of ciprofloxacin. The inactive ingredients are povidone, glycerin, and water for injection. Sodium hydroxide and/or lactic acid may be added to adjust pH.

Ciprofloxacin, a fluroquinolone is available as the monohydrochloride, monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its molecular formula is C 17H 18FN 3O 3•HCl•H 2O, and molecular weight is 385.82. 

The chemical structure of ciprofloxacin hydrochloride is:
An agent application executing on a computing device identifies a patient health record for a patient based upon an identifier for the patient. The patient health record comprises an identifier for a healthcare facility at which a clinical event of the patient occurred and information about the clinical event. The agent application transmits the identifier for the healthcare facility to a mapping computing system that retrieves a map of an area encompassing the healthcare facility based upon the identifier for the healthcare facility. The map includes a marker that marks a location of the healthcare facility. Responsive to receiving the map, the agent application causes a graphical indicator to be included in the map proximate to the marker, the graphical indicator including the identifier for the healthcare facility and the information about the clinical event. The agent application causes the map to be displayed on a display.
Venlafaxine hydrochloride extended-release capsules, USP are extended-release capsule for once-a-day oral administration that contains venlafaxine hydrochloride, USP a serotonin and norepinephrine reuptake inhibitor (SNRI). 

Venlafaxine is designated as 1–[(1RS)-2-(Dimethylamino)-1-(4-Methoxy phenyl) ethyl] cyclohexanol hydrochloride and has the empirical formula of C17H28ClNO2. Its molecular weight is 313.9. The structural formula is shown as follows: 

Venlafaxine hydrochloride USP is an off-white to white crystalline powder, soluble in methanol and water. Its partition coefficient is 0.1.

Drug release is controlled by diffusion through the coating membrane on the Spheroids and is not pH dependent. Capsules contain venlafaxine hydrochloride, USP equivalent to 37.5 mg, 75 mg, or 150 mg venlafaxine. Inactive ingredients consist of ethyl cellulose, ferric oxide red, gelatin, hypromellose, methyl alcohol, methylene chloride, microcrystalline cellulose, talc and titanium dioxide. In addition to the above 37.5mg consists of ferric oxide black and ferric oxide yellow.

The components of the black imprinting ink used in the venlafaxine hydrochloride extended-release capsules USP, 37.5 mg and 75 mg are black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.

The components of the white imprinting ink used in the venlafaxine hydrochloride extended-release capsules USP, 150 mg are butyl alcohol, dehydrated alcohol, isopropyl alcohol, povidone, propylene glycol, shellac, sodium hydroxide and titanium dioxide.

Dissolution Test specification differ from USP.
OBJECTIVE: Magnetic resonance (MR) relaxometry is an absolute and reproducible quantitative method, compared with signal intensity for the evaluation of liver biliary function. This is obtainable by the T1 reduction rate (T1RR), as it carries a smaller systematic error than the pre/post contrast agent T1 measurement. We aimed to develop and test an MR T1 relaxometry tool tailored for the evaluation of liver T1RR after gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid administration on 1.5T MR.
METHODS: In vitro/vivo (liver) T1RR values with two 3D FLASH variable-flip-angle sequences were calculated by a MATLAB algorithm. In vitro measurements were done by 2 physicists, in consensus. The prospective in vivo study was approved by the local ethical committee and performed on 13 normal/26 cirrhotic livers. A supplemental test in 5 normal/5 cirrhotic livers, out of the studied series, was done to compare the results of our method (without B1 inhomogeneity correction) and those of a standardized commercial tool (with B1 inhomogeneity correction). All in vivo evaluations were performed by 2 radiologists with 7 years of experience in abdominal imaging. Open-source Java-based software ImageJ was used to draw the free-hand regions of interest on liver section and for the measurement of hepatic T1RR values. The T1RR values of each group of patients were compared to assess statistically significant differences. All statistical analyses were performed with IBM-SPSS Statistics. In vivo evaluations, the intrareader and interreader reliability was assessed by intraclass correlation coefficient.
RESULTS: Our method showed good accuracy in evaluating in vitro T1RR with a maximum percentage error of 9% (constant at various time points) with T1 values in the 200- to 1400-millisecond range. In vivo, a high concordance between the T1RR evaluated with the proposed method and that calculated from the standardized commercial software was verified ( P < 0.05). The median T1RRs were 74.8, 67.9, and 52.1 for the normal liver, Child-Pugh A, and Child-Pugh B cirrhotic groups, respectively. A very good agreement was found, both within intrareader and interreader reliability, with intraclass correlation coefficient values ranging from 0.88 to 0.95 and from 0.85 to 0.90, respectively.
CONCLUSIONS: The proposed method allowed accurate reliable in vitro/vivo T1RR assessment evaluation of the liver biliary function after gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid administration.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common worldwide. Genes and proteins contributing to drug disposition may show altered expression as MASLD progresses. To assess this further, we undertook transcriptomic and proteomic analysis of 137 pharmacogenes in liver biopsies from a large MASLD cohort. We performed sequencing on RNA from 216 liver biopsies (206 MASLD and 10 controls). Untargeted mass spectrometry proteomics was performed on a 103 biopsy subgroup. Selected RNA sequencing signals were replicated with an additional 187 biopsies. Comparison of advanced MASLD (fibrosis score 3/4) with milder disease (fibrosis score 0-2) by RNA sequencing showed significant alterations in expression of certain phase I, phase II and ABC transporters. For cytochromes P450, CYP2C19 showed the most significant decreased expression (30 % of that in mild disease) but significant decreased expression of other CYPs (including CYP2C8 and CYP2E1) also occurred. CYP2C19 also showed a significant decrease comparing the inflammatory form of MASLD (MASH) with non-MASH biopsies. Findings for CYP2C19 were confirmed in the replication cohort. Proteomics on the original discovery cohort confirmed decreased levels of several CYPs as MASLD advanced but this decrease was greatest for CYP2C19 where levels fell to 40 % control. This decrease may result in decreased CYP2C19 activity that could be problematic for prescription of drugs activated or metabolized by CYP2C19 as MASLD advances. More limited decreases for other P450s suggest fewer issues with non-CYP2C19 drug substrates. Negative correlations at RNA level between CYP2C19 and several cytokine genes provided initial insights into the mechanism underlying decreased expression.
The MED diet was abundant in fiber, micronutrients and plant-based proteins. The diet was rich in essential FA like monounsaturated fatty acids (MUFA) and n-3.
Amino acid cyclic amide derivatives (I) are new. Amino acid cyclic amide derivatives of formula (I) are new. B-A-C (I) A : an alpha -amino acid with a side-chain functional group; B : a molecule covalently bonded to the side-chain functional group of A, selected from oligopeptides with a chain length of up to 20 amino acids, polyethylene glycol (PEG) with a molecular weight of up to 20,000, optionally substituted organic amines, amides, alcohols, acids or aromatics with 8-50 C atoms; C : a thiazolidine (Thia), pyrrolidine, hydroxyproline, dehydroproline or piperidine group forming an amide bond with A. ACTIVITY : Antiinflammatory; antiallergic; dermatological; antiarthritic; antipsoriatic; immunomodulator; cytostatic. MECHANISM OF ACTION : Dipeptidyl peptidase IV (DP IV) modulator. The serum DP IV activity of rats after oral administration of 5 mu M Glu(PEG)-Thia was increased by almost 10% after 20 minutes and then decreased to 90% of the initial level over the next 100 minutes.
The method involves using a digital badge device worn on the chest of a user to visually convey personal attributes to others in line of sight. It begins by configuring the badge device to communicate wirelessly with the user's mobile device. Next, a personal attribute of the user is determined based on input from the user or device-captured data. This attribute could relate to the user's affiliation, emotional state, physical activity, and more. Finally, a pre-defined color and/or symbol code representing the determined attribute is displayed on the badge device's screen for others to see. This provides an easily interpretable visual cue to communicate specific personal attributes to different users. By employing this method, the badge wearer can convey information about themselves without the need for verbal communication. The method offers a convenient and efficient way to signal personal attributes in situations where direct interaction may be limited or impractical.
Patients with decompensated liver cirrhosis, in particular those classified as Childs-Pugh class C, are at increased risk of severe coronavirus disease-2019 (COVID-19) upon infection with severe acute respiratory coronavirus 2 (SARS-CoV-2). The biological mechanisms underlying this are unknown. We aimed to examine the levels of serum intrinsic antiviral proteins as well as alterations in the innate antiviral immune response in patients with decompensated liver cirrhosis. Serum from 53 SARS-CoV-2 unexposed and unvaccinated individuals, with decompensated liver cirrhosis undergoing assessment for liver transplantation, were screened using SARS-CoV-2 pseudoparticle and SARS-CoV-2 virus assays. The ability of serum to inhibit interferon (IFN) signalling was assessed using a cell-based reporter assay. Severity of liver disease was assessed using two clinical scoring systems, the Child-Pugh class and the MELD-Na score. In the presence of serum from SARS-CoV-2 unexposed patients with decompensated liver cirrhosis there was no association between SARS-CoV-2 pseudoparticle infection or live SARS-CoV-2 virus infection and severity of liver disease. Type I IFNs are a key component of the innate antiviral response. Serum from patients with decompensated liver cirrhosis contained elevated levels of auto-antibodies capable of binding IFN-α2b compared to healthy controls. High MELD-Na scores were associated with the ability of these auto-antibodies to neutralize type I IFN signalling by IFN-α2b but not IFN-β1a. Our results demonstrate that neutralizing auto-antibodies targeting IFN-α2b are increased in patients with high MELD-Na scores. The presence of neutralizing type I IFN-specific auto-antibodies may increase the likelihood of viral infections, including severe COVID-19, in patients with decompensated liver cirrhosis.
NEW MATERIAL:A compound, obtained from an aqueous layer extracted from a mycoplasma culture with cloroform:methanol and having the following properties. Activating antitumor cytotoxic activity of macrophage. Somewhat unstable to alkalis (inactivated by allowing to stand in 1N NaOH at ambient temperature for 24hr). Stable to acids (by allowing to stand in 1N HCl at ambient temperature for 24hr), heat (at 100 deg.C for 5min), freezing, melting, proteolytic enzymes, etc. Passing through a lectin column and cation exchanger column without adsorption and held by an anion exchanger. USE:An antitumor agent. PREPARATION:For example, mycoplasma is cultured and centrifuged at a high sped to collect microbial cells, which are then suspended in a phosphoric acid buffer solution and extracted with chloroform:methanol (1:2). An aqueous layer is separated from an organic layer and fractionated by high-speed liquid chromatography to afford the aimed macrophage activating factor from the resultant fraction having macrophage activating function.
The invention provides an externally applied gel for treating gout, which is an externally applied medicine made from traditional Chinese medicine components such as nidus vespae, colchicine, a gel matrix, and the like., and by taking a coupling medium as transdermal carrier. The anti-gout gel can quickly eliminate redness, swelling, pain and fever symptoms of gouty arthritis, inhibit granulocyte infiltration and formation of lactic acid, reduce synthesis of uric acid, shorten and stop the acute attack of the gouty arthritis, prevent gout complications that threaten life, suspend tissue and organ damage caused by deposition of the uric acid, thus ensure that the illness of a patient is stabilized and can not deteriorate anymore for a long time. With the coupling medium adopted as the transdermal carrier of the medicine, the gel is characterized in that: a dermal hydration gradient can be naturally formed in the skin permeation course of the coupling medium, the gradient is independent of concentration when driving osmotic pressure difference, the gel has high deformability, can keep the components thereof unchanged after the skin permeation course and can permeate corneum of mammals through a plurality of transformation. The gel also has high transdermal efficiency, and full dermal permeabilities are not different between species and different parts. The gel avoids the deficiencies of injections and oral liquid medicines, is safe owing to the external use, and has no toxicity and side effects. The gel has simple components, low cost, requires no special devices and production conditions, and is available for large-scale industrialized production.
PURPOSE:To provide an antiallergic agent containing a deazapyrimidine derivative. CONSTITUTION:The objective antiallergic agent is produced by using a deazapyrimidine derivative (e.g. sangivamycin, toyocamycin, tubercidin, its aglicone or a compound obtained by adding phenyl group. cyclohexane, etc. to the 7-N of the above antibiotics) as an active component. The present agent has been prepared based on the newly found facts that the pyrimidine derivative toyocamycin and its derivative are effective to the prevention and remedy for the immediate allergic diseases such as bronchial asthma because the compound suppresses specifically the I-type allergic reaction with IgE and relaxes the bronchial smooth muscle, and that the above active component remarkably suppresses the immediate allergic reaction in vitro and in vivo.
<P>PROBLEM TO BE SOLVED: To provide a semisolid detergent entering into a detergent market based on a new aspect, and overcoming disadvantages of a gel-like detergent which is an intermediate between solid and liquid detergents and is unsuitable for repeated use due to its low physical strength, thus pointed out to be insufficient by consumers.  <P>SOLUTION: The present inventors have studied various combinations of polysaccharides effective to retain solid part of a detergent in order to improve physical properties of such solid part. As a result, a combination of konjak mannan and carageenan or konjak mannan and xanthane gum is confirmed to be effective. The detergent comprising a solid part consisting of such a combination has considerably improved "rupture strength" and "tensile strength" compared to commercially available gel-type detergents, and is called as a "semisolid detergent". The physical properties of the detergent can be freely controlled by altering the ratio and amount to be compounded. The detergent can be used as a raw material of other liquid detergents.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Dementia limits timely revascularization in individuals with acute myocardial infarction (AMI). However, it remains unclear whether dementia affects prognosis negatively in older individuals with AMI in the intensive care unit (ICU). This research aimed to evaluate the dementia effect on the outcomes in individuals with AMI in ICU.Data from 3,582 patients aged ≥ 65 years with AMI in ICU from the Medical Information Mart for Intensive Care IV (MIMIC IV) database were evaluated. The independent variable was dementia at baseline, and the primary finding was death from any cause during follow-up. A 1:1 propensity score matching (PSM) showed 208 participants with and without dementia. The correlation between dementia and poor prognosis of AMI was verified using a double-robust estimation method.In the PSM cohort, the 30-day all-cause mortality was 37.50% and 33.17% in the dementia and non-dementia groups (P = 0.356), respectively, and the 1-year all-cause mortality was 61.06% and 51.44%, respectively (P = 0.048). Cox regression analysis showed no association between dementia and elevated 30-day (hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.84, 1.60) and 1-year (HR 1.28, 95% CI 0.99, 1.66) all-cause mortality after AMI. Similarly, dementia was not connected with in-hospital mortality, bleeding, or stroke after AMI. Interaction analysis showed that 1-year all-cause mortality was 48.00% higher in individuals with dementia and diabetic complications than in those without diabetic complications.Dementia is not an independent risk factor for adverse outcomes in AMI. Thus, it may be inappropriate to include dementia as a contraindication for invasive AMI therapy.
Subjects are randomized to walking/functional strength program with weekly coaching or usual care. The program is for 12 weeks. The intervention includes 3 lower extremity strengthening exercises, and progressive walking.
If possible, all included participants are physically followed home by a hospital-based project worker on the day of discharge. During the visit, the focus is on: basic human needs, medication review reconciliation, and a comprehensive geriatric assessment. Problems, challenges and concerns are discussed. Finally, a conference for the following working day is arranged either as a physical visit or a video conference. The patient, relatives, community-based nurse and project worker are invited to participate and health status and challenges are discussed They are recommended to contact the project worker about health and practical issues up to 7 days after discharge where the intervention ends. Subsequently, the responsibility for treatment and care is assigned to the GP and home healthcare provider.
The present invention provides a dressing with anesthetic effect for use in the oral cavity that comprises a dose of an anesthetic substance for topical use contained, impregnated or embedded in a harmless envelope and/or harmless support that allows the localized release of the anesthetic substance. for topical use. With this dressing the application and release of the anesthetic substance in the oral cavity is achieved in a more localized way than with an anesthetic gel, which is easily spread throughout the mouth. The dressing, having a dose known in advance and being supported or contained or impregnated in an envelope or support, is very suitable to be individually dispensed to patients waiting to be treated in a waiting room and applied by themselves to the area to be treated for exactly five to ten minutes before going to the treatment room. In this way, the treatment time by the dentist is considerably reduced without impairing the tranquility of the patient when receiving the injection of infiltrative anesthetic after having applied a topical local anesthetic because it greatly reduces the acute pain of an injection in the gums. (Machine-translation by Google Translate, not legally binding)
RIC sham interventions will be applied to the upper extremity for a total of 20 cumulative minutes. For sham, inflation will occur.
Cohort 3 - LAT followed by Osimertinib. Participants may undergo 1 of 3 local ablative procedures after initial progression on Osimertinib: surgery, radiotherapy, radiofrequency ablation. The starting dose of Osimertinib will be 80 mg per day for participants without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline. Single daily dose of Osimertinib until progression.
Luminal breast cancer has a high incidence worldwide and poses a severe health threat. Estrogen receptor alpha (ER-α) is activated by 17β-estradiol (E2), and its overexpression promotes cancerous characteristics. Luminal breast cancer is an epithelial type; however, the cytokine IL-6, secreted by cells within the tumor microenvironment, stimulates the epithelial-to-mesenchymal transition (EMT) and promotes metastasis. Also, IL-6 decreases ER-α levels, favoring the tamoxifen (TMX) resistance development. However, genes under E2 regulation continue to be expressed even though this receptor is absent. GPR30 is an alternative E2 receptor present in both luminal and aggressive triple-negative breast cancer and is related to TMX resistance and cancer progression. The roles of GPR30 and IL-6 in metastasis have been individually established; however, their interplay remains unexplored. This study aims to elucidate the role of GPR30 in IL-6-induced metastatic properties of MCF-7 luminal breast cancer cells. Results showed that GPR30 contributes to the E2-induced MCF-7 proliferation because its inhibition with the antagonist G15 and the Pertussis toxin (PTX) reduced it. Besides, GPR30 upregulated vimentin and downregulated E-cadherin levels in MCF-7 and TMX-resistant (R-TMX) cells and is also involved in the IL-6-induced migration, invasion, and TMX resistance in MCF-7 cells. In addition, in MDA-MB-231 triple-negative cells, both basal and IL-6-induced metastatic properties were related to GPR30 activity. These results indicate that the GPR30 receptor regulates the EMT induced by IL-6 in breast cancer cells.
Teratogenic Effects

Pregnancy Category D [see Warnings and Precautions (5.6)].

Based on its mechanism of action, fludarabine phosphate can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of fludarabine phosphate in pregnant women. In rats, repeated intravenous doses of fludarabine phosphate at 2.4 times and 7.2 times the recommended human IV dose (25 mg/m2) administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations (cleft palate, exencephaly, and fetal vertebrae deformities) and decreased fetal body weights. Maternal toxicity was not apparent at 2.4 times the human IV dose, and was limited to slight body weight decreases at 7.2 times the human IV dose. In rabbits, repeated intravenous doses of fludarabine phosphate at 3.8 times the human IV dose administered during organogenesis increased embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses. A significant increase in malformations including cleft palate, hydrocephaly, adactyly, brachydactyly, fusions of the digits, diaphragmatic hernia, heart/great vessel defects, and vertebrae/rib anomalies were seen in all dose levels (≥ 0.5 times the human IV dose). If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.